The Pap Test and Bethesda 2014

The history of ‘The Bethesda System' for reporting cervical cytology goes back almost 3 decades. This terminology and the process that created it have had a profound impact on the practice of cervical cytology for laboratorians and clinicians alike. The Bethesda conferences and their ensuing output have also set the stage for standardization of terminology across multiple organ systems, including both cytology and histology, have initiated significant research in the biology and cost-effective management for human papillomavirus-associated anogenital lesions, and, finally, have fostered worldwide unification of clinical management for these lesions. Herein, we summarize the process and rationale by which updates were made to the terminology in 2014 and outline the contents of the new, third edition of the Bethesda atlas and corresponding website.

[1]  R. Bardales.  The Bethesda System for reporting cervical/vaginal cytologic diagnoses: Definitions, criteria, and explanatory notes for terminology and specimen adequacy:Robert J. Kurman and Diane Solomon (eds). New York, NY, Springer-Verlag, 1994, 81 pages, $25 , 1994 .

[2]  J. T. Cox,et al.  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. , 2012, Journal of lower genital tract disease.

[3]  M. Schiffman,et al.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. , 2001, JAMA.

[4]  D. Wilbur,et al.  Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. , 2009, Archives of pathology & laboratory medicine.

[5]  L. Layfield,et al.  Pancreaticobiliary tract cytology: Journey toward “Bethesda” style guidelines from the Papanicolaou Society of Cytopathology , 2014, CytoJournal.

[6]  Thomas C Wright,et al.  Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities , 2002 .

[7]  Thomas C Wright,et al.  2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. , 2002, Journal of lower genital tract disease.

[8]  David C Wilbur,et al.  The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. , 2012, Journal of lower genital tract disease.

[9]  Diane Solomon,et al.  Risk assessment to guide the prevention of cervical cancer. , 2007, American journal of obstetrics and gynecology.

[10]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[11]  D. Solomon,et al.  The Bethesda system for reporting cervical cytology : definitions, criteria, and explanatory notes , 2004 .

[12]  C. Brown,et al.  The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. , 1990, Acta cytologica.

[13]  Diane Solomon,et al.  The Bethesda interobserver reproducibility study (BIRST) , 2006, Cancer.

[14]  Diane Soloman,et al.  The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses: Developed and approved at the national cancer institute workshop in Bethesda, MD, December 12–13, 1988 , 1989, Diagnostic cytopathology.

[15]  Diane Solomon,et al.  2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. , 2007, American journal of obstetrics and gynecology.

[16]  Diane Solomon,et al.  The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses , 1994, Springer US.

[17]  Robert P Berkowitz,et al.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. , 2013, Obstetrics and gynecology.

[18]  Diane Solomon,et al.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. , 2013, Obstetrics and gynecology.